Predicting response to EGFR-tyrosine kinase inhibitors among diverse ancestries: just way too polymorphic.
Zbuk
Kevin M
KM
Genomic Medicine Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Eng
Charis
C
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000235:genetics*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D011110:Polymorphism, Genetic; D047428:Protein Kinase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors